Last checked at 28 Apr 2020 10:06
28 April 2020
Scancell Holdings plc
("Scancell" or the "Company")
Director Dealing
Scancell (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer announces that Vulpes Life Science Fund, a person closely associated with Martin Diggle, Non- Executive Director, has sold 1,500,000 ordinary shares of 0.1p each ('Ordinary Shares') in the Company on 27 April 2020 at a price of 8p per share. Following the sale, Vulpes Life Science Fund holds 78,549,311 ordinary shares representing 16.9% of the company.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Vulpes Life Science Fund |
2 | Reason for the notification | |
a) | Position/status | Person closely associated with Martin Diggle, Non-Executive Director |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Scancell Holdings plc |
b) | LEI | 2138008RXEG856SNP666 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.1 pence each |
b) | Identification Code | GB00B63D3314 |
c) | Nature of the transaction | Sale of Ordinary Shares |
d) | Price(s) and volume(s) | 1,500,000 Ordinary Shares 8 pence per Ordinary Share |
e) | Aggregated information - Aggregated volume - Price |
N/A (single transaction)
|
f) | Date of the transaction | 27 April 2020 |
g) | Place of the transaction | London Stock Exchange, AIM |
- ENDS -
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).
For more information, please contact:
Scancell Holdings plc | +44 (0)20 3727 1000 |
Dr John Chiplin, Chairman | |
Dr Cliff Holloway, CEO | |
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl | |
Corporate Broking: James Stearns | |
FTI Consulting | +44 (0)20 3727 1000 |
Simon Conway | |
Natalie Garland-Collins |
Notes for Editors
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
· SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.
Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
· Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.
AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.
In response to the COVID-19 pandemic, Scancell has turned its clinical expertise in cancer to produce a simple, safe, cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against SARS-Cov-2, the virus that causes COVID-19. The Company believes this combined T cell and antibody approach should give more potent and long-lasting responses, ultimately leading to better protection.
For further details, please see our website: www.scancell.co.uk